What question did this study set out to answer?

The aim is to examine the undetectability rates of HDV RNA during bulevirtide monotherapy.

May 11, 2026Liver International0 citations

HDV RNA Undetectability Rates During Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta May Be Assay Dependent

MAMaria Paola AnolliUniversity of Milan SRSara Uceda RenteriaUniversity of Milan EDElisabetta DegasperiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Key Points

The aim is to examine the undetectability rates of HDV RNA during bulevirtide monotherapy.
Monotherapy with bulevirtide conducted in patients with chronic hepatitis delta.
Focus on assay-dependent variability in undetectability rates.
Observed differences in undetectability rates based on the assay used.
No specific statistical outcomes reported in the abstract.

Abstract

Elisabetta Degasperi: Advisory Board: AbbVie; Speaking and teaching: Gilead, MSD, AbbVie; Pietro Lampertico: Advisor and speaker bureau for Roche Pharma/Diagnostics, Gilead Sciences, Gsk, Abbvie, Janssen, Myr, Eiger, Antios, Aligos, Vir, Grifols, Altona, Roboscreen. Other authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

问 AI

Bookmark

View Full Paper